Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer
NCT ID: NCT00900523
Last Updated: 2013-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
7 participants
OBSERVATIONAL
2006-11-30
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is measuring the amount of prostaglandin metabolite in urine samples from patients with ovarian cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT01096394
Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary
NCT00626873
Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study
NCT06800105
Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom
NCT00757263
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
NCT04794322
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the level of prostaglandin E\_2 metabolite (PGE-M) in 24-hour urine samples collected prior to surgery or chemotherapy from patients with ovarian cancer.
* Determine cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) expression by western blot and immunohistochemistry (IHC) in ovarian tumor tissue samples and matched normal ovarian tissue samples, if available, from these patients.
* Correlate urine PGE-M levels with corresponding tissue COX-1 and COX-2 levels in urine and tissue samples from these patients.
OUTLINE: This is a pilot study.
Patients submit 24-hour urine specimens prior to surgery for evaluation of urinary levels of prostaglandin E\_2 metabolite (PGE-M).
Patients also undergo assessment of tissue obtained at the time of surgery, including ovarian tumor tissue, normal surface ovarian epithelium tissue (if available), and fixed tissue embedded in a paraffin block. Tissue samples are analyzed by western blot and IHC for cyclooxygenase-1 and cyclooxygenase-2 expression.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Known or suspected ovarian cancer
Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
protein expression analysis
protein expression analysis
immunohistochemistry
immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
protein expression analysis
protein expression analysis
immunohistochemistry
immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age greater than 17 years
Exclusion Criteria
* Taking steroids or non-steroidal anti-inflammatory drugs (NSAIDs) on a regular basis.
PRIOR CONCURRENT THERAPY:
* No concurrent chronic use of steroids or NSAIDs
17 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marta Crispens, MD
Associate Professor; Gynecological Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marta Crispens, MD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt-Ingram Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VU-VICC-GYN-0648
Identifier Type: -
Identifier Source: secondary_id
VU-VICC-IRB-060680
Identifier Type: -
Identifier Source: secondary_id
VICC GYN 0648
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.